<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962074</url>
  </required_header>
  <id_info>
    <org_study_id>2019</org_study_id>
    <nct_id>NCT04962074</nct_id>
  </id_info>
  <brief_title>Sperm Selection and Embryo Development: Comparison of the Density Gradient Centrifugation and Microfluidic Chip Sperm Preparation Methods Sperm Selection and Embryo Development: Comparison of the Density Gradient Centrifugation and Microfluidic Chip Sperm Preparation Methods</brief_title>
  <official_title>Sperm Selection and Embryo Development: Comparison of the Density Gradient Centrifugation and Microfluidic Chip Sperm Preparation Methods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maltepe University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maltepe University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To compare the effects of the density gradient centrifugation and microfluidic chip&#xD;
      sperm preparation methods on embryo development in a study population with&#xD;
      astheno-teratozoospermia.&#xD;
&#xD;
      Materials and Methods: In this prospective study, the semen samples of the patients with&#xD;
      astheno-teratozoospermia were divided into two groups for preparation with either the&#xD;
      microfluidic or density gradient methods. Selected spermatozoa were used to fertilize the&#xD;
      mature sibling oocytes. Semen parameters and embryo development on days 3 and 5 were&#xD;
      assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2020</start_date>
  <completion_date type="Actual">September 20, 2020</completion_date>
  <primary_completion_date type="Actual">September 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Semen parameters after sperm preparation with either method: semen volume</measure>
    <time_frame>up to 7 months</time_frame>
    <description>semen volume (ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semen parameters after sperm preparation with either method: sperm concentration</measure>
    <time_frame>up to 7 months</time_frame>
    <description>sperm concentration (106/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semen parameters after sperm preparation with either method: total motility</measure>
    <time_frame>up to 7 months</time_frame>
    <description>total motility (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semen parameters after sperm preparation with either method: progressive motility</measure>
    <time_frame>up to 7 months</time_frame>
    <description>progressive motility (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Embryo development after sperm preparation with either method</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Embryo development and blastocyst formation were evaluated on days 1, 3 and 5 based on the criteria reported by Veeck and Zaninovic, 2003</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Reduced Sperm Motility</condition>
  <condition>IVF</condition>
  <condition>ICSI</condition>
  <condition>Astheno Teratozoospermia</condition>
  <arm_group>
    <arm_group_label>Density gradient method</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sperm prepared by density gradient method</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microfluidic chip</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sperm prepared by microfluidic chip method</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microfluidic sperm sorting chip</intervention_name>
    <description>Fertile UltimateÂ® (Koek Biotechnology, Turkey) microfluidic sperm sorting chips</description>
    <arm_group_label>Microfluidic chip</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Density gradient</intervention_name>
    <description>Density gradient centrifugation</description>
    <arm_group_label>Density gradient method</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infertile men with astheno-teratozoospermia&#xD;
&#xD;
          -  Women were aged from 18 to 39&#xD;
&#xD;
          -  Women had at least two mature oocytes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MI oocytes&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Split semen samples from the same population of infertile men with astheno-teratozoospermia were used to fertilize the mature sibling oocytes.</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MaltepeU</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 25, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sperm</keyword>
  <keyword>IVF</keyword>
  <keyword>ICSI</keyword>
  <keyword>Abnormal morphology of sperm</keyword>
  <keyword>Astheno Teratozoospermia</keyword>
  <keyword>Microfluidic chip</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teratozoospermia</mesh_term>
    <mesh_term>Asthenozoospermia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

